Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Smouldering multiple myeloma, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No trial has shown that treating smouldering myeloma lengthens life rather than delaying the label of active disease.
Risk models still misclassify many patients in both directions.
Whether curative-intent treatment of a precursor is justified, and for whom.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
With teclistamab after ≥1 line (MajesTEC-3); high-risk smouldering myeloma (AQUILA)
A milestone in how this cancer is treated.
Subcutaneous daratumumab delayed progression to active myeloma or death compared with active monitoring in high-risk smouldering myeloma; approved in the United States in 2025.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.